Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644625 · ClinicalTrials.gov registry record
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
A clinical trial of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS), sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 1,665
- Enrollment target
- 1
- Study location
NCT06644625: Recruiting study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS), sponsored by Wake Forest University Health Sciences.
NCT06644625 is a study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS) that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 1,665 participants, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (207% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06644625, a study of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance (MGUS), is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 1,665 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
Primary Outcome
Determined for each potential participant approached to participate in this study (pre-screened), indicating whether or not the participant was enrolled (underwent blood draw to test for monoclonal gammopathy).
Conditions Studied
Interventions
- OTHER Blood draw for the laboratory assessment
Study Locations (1)
North Carolina
- Atrium Health Levine Cancer - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,665 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2035-01 |
What NCT06644625 shows while recruiting
NCT06644625 is an observational study that tracks outcomes without assigning an intervention. Its 1,665 participants enrollment target places it among the larger protocols in the corpus, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (207% higher).
The record links to 5 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Blood draw for the laboratory assessment is the first listed.
NCT06644625 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06644625 about?
NCT06644625 is a clinical study titled "CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study". The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.
What is the current status of trial NCT06644625?
This trial is currently recruiting. The enrollment target is 1,665 participants. The study started on 2025-03-01. Estimated completion is 2035-01.
What conditions does trial NCT06644625 study?
This clinical trial studies the following conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Plasma Cell Disorders, Multiple Myeloma Progression.
What interventions are being tested in trial NCT06644625?
The interventions under investigation include: Blood draw for the laboratory assessment (OTHER).
Who is sponsoring clinical trial NCT06644625?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644625 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06644625's enrollment target sits among peer trials
1,665 14th of 438 higher than 425 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06034405 · 1,663 participants
Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
- NCT04852887 · 1,670 participants · Phase 3
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
- NCT06376565 · 1,680 participants · NA
Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI